Vitamin K antagonists in heart disease: Current status a

Thrombosis and Haemostasis
110, 1087-1107
DOI: 10.1160/th13-06-0443

Citation Report

#	Article	IF	Citations
1	February 11, 1964. Clin-Alert, 1964, 2, 11-13.	0.3	1
2	Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. Thrombosis and Haemostasis, 2014, 112, 511-521.	1.8	69
3	Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. PLoS ONE, 2014, 9, e114445.	1.1	54
4	Response to Ansell et al. â€œNon-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novelâ€. Thrombosis and Haemostasis, 2014, 112, 842-842.	1.8	6
5	Stroke and Bleeding Risk in Atrial Fibrillation. Korean Circulation Journal, 2014, 44, 281.	0.7	32
6	Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. Thrombosis and Haemostasis, 2014, 112, 918-923.	1.8	58
7	Patientâ€™s values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. Thrombosis and Haemostasis, 2014, 112, 381-383.	1.8	64
8	Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 789-795.	1.8	16
9	Eficacia y seguridad del tratamiento anticoagulante oral con antagonistas de vitamina K en pacientes con prÃ³tesis valvulares cardÃacas. Revista Chilena De CardiologÃa, 2014, 33, 27-32.	0.0	2
10	Differences among western European countries in anticoagulation management of atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 833-841.	1.8	96
11	Editorial (Thematic Issue: â€˜Loneâ€™ Atrial Fibrillation: No Longer Lone or Even Alone). Current Pharmaceutical Design, 2014, 21, 531-532.	0.9	2
12	Solving the mystery of excessive warfarin-induced bleeding: A personal historical perspective. Thrombosis and Haemostasis, 2014, 112, 853-856.	1.8	3
13	Stroke Prevention in Asian Patients With Atrial Fibrillation. Stroke, 2014, 45, 1608-1609.	1.0	12
14	Atrial fibrillation and retinal vein or artery occlusion: looking beyond the eye: TableÂ1. British Journal of Ophthalmology, 2014, 98, 1141-1143.	2.1	18
15	Updated NICE guideline: management of atrial fibrillation (2014). Expert Review of Cardiovascular Therapy, 2014, 12, 1037-1040.	0.6	32
16	Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders. Clinical Investigation, 2014, 4, 619-639.	0.0	2
17	Response. Chest, 2014, 145, 419-420.	0.4	1
18	Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants. BioMed Research International, 2014, 2014, 1-14.	0.9	6

#	Article	IF	Citations
19	Relationship of the SAMe-TT 2 R 2 Score to Poor-Quality Anticoagulation, Stroke, Clinically Relevant Bleeding, and Mortality in Patients With Atrial Fibrillation. Chest, 2014, 146, 719-726.	0.4	108
20	Nonâ€"Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation and Venous Thromboembolism: Where are we Now?. Hospital Practice (1995), 2014, 42, 153-162.	0.5	2
21	Atrial fibrillation and stroke prevention: brief observations on the last decade. Expert Review of Cardiovascular Therapy, 2014, 12, 403-406.	0.6	13
22	Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF) Tj ETQq1 1 0.784314 rgBT /Over	0.7	298
23	Warfarin or dabigatran for treatment of atrial fibrillation. Journal of Thrombosis and Haemostasis, 2014, 12, 1193-1195.	1.9	5
24	Dabigatran etexilate for venous thromboembolism: a safety evaluation. Expert Opinion on Drug Safety, 2014, 13, 639-647.	1.0	4
25	Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thrombosis Journal, 2014, 12, 24.	0.9	45
26	Which drug should we use for stroke prevention in atrial fibrillation?. Current Opinion in Cardiology, 2014, 29, 293-300.	0.8	7
27	Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thrombosis and Haemostasis, 2014, 112, 781-782.	1.8	142
29	â€˜Real-Worldâ€™ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey. American Journal of Medicine, 2014, 127, 519-529.e1.	0.6	144
30	Atrial fibrillation â€¦ more than simply being irregularly irregular. International Journal of Clinical Practice, 2014, 68, 408-409.	0.8	0
31	Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. Cardiology Clinics, 2014, 32, 585-599.	0.9	7
32	New advances in the treatment of atrial fibrillation: focus on stroke prevention. Expert Opinion on Pharmacotherapy, 2014, 15, 2193-2204.	0.9	4
33	The Reply. American Journal of Medicine, 2014, 127, e21.	0.6	0
34	Specific risk scores for specific purposes: Use CHA2DS2-VASc for assessing stroke risk, and use HAS-BLED for assessing bleeding risk in atrial fibrillation. Thrombosis Research, 2014, 134, 217-218.	0.8	11
35	Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation. Current Problems in Cardiology, 2014, 39, 319-344.	1.1	5
36	Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor. Drugs, 2014, 74, 1209-1231.	4.9	84
37	Using the CHA2DS2-VASc Score for Refining Stroke Risk Stratification inÂâ€˜Low-Riskâ€™ Asian Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 64, 1658-1665.	1.2	157

#	Article	IF	Citations
38	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. European Heart Journal, 2014, 35, 3155-3179.	1.0	490
39	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace, 2014, 16, 1655-1673.	0.7	105
40	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	1.0	2,591
41	One Weapon, Two Blows in the War Against the Thrombus. Journal of the American College of Cardiology, 2014, 63, 2699-2701.	1.2	2
42	Atrial Fibrillation and Heart Failure: A Bad Combination. American Journal of Cardiology, 2014, 113, 1196-1197.	0.7	9
43	Comparing the â€˜Newâ€™ R2CHADS2 With the â€˜Oldâ€™ CHA2DS2-VASc Scores for Predicting Thromboembolism in Patients Undergoing Atrial Fibrillation Ablation: New Does Not Mean Better. Canadian Journal of Cardiology, 2014, 30, 385-387.	0.8	1
44	SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation. American Journal of Medicine, 2014, 127, 1083-1088.	0.6	112
45	MY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation*. Trends in Cardiovascular Medicine, 2014, 24, 265-266.	2.3	2
46	Impact of Non-Vitamin K Antagonist Oral Anticoagulants on Intracranial Bleeding in Asian Patients With Non-Valvular Atrial Fibrillation. Circulation Journal, 2014, 78, 2367-2372.	0.7	46
47	Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 981-988.	1.8	99
48	The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. Thrombosis and Haemostasis, 2014, 112, 1080-1087.	1.8	60
49	Modern Management of Atrial Fibrillation Requires Initial Identification of â€œLow-Riskâ€•Patients Using the CHA₂DS₂-VASc Score, and Not Focusing on â€œHigh-Riskâ€• Prediction. Circulation Journal, 2014, 78, 1843-1845.	0.7	26
50	Stroke and Bleeding Risk in Atrial Fibrillation: Navigating the Alphabet Soup of Riskâ€Score Acronyms (CHADS₂, CHA₂DS₂â€VASc, R₂CHADS₂,) Tj ETQq0 0 0 rgBT /Overloc		
51	Stroke prevention in atrial fibrillation: An Asian perspective. Thrombosis and Haemostasis, 2014, 112, 789-797.	1.8	231
52	Non-Vitamin K Antagonist Oral Anticoagulants. Chest, 2014, 145, 1177-1178.	0.4	17
53	Atrial Fibrillation During Sepsis. Chest, 2014, 146, 1138-1140.	0.4	2
54	Assessing Bleeding Risk With the <scp>HASâ€BLED</scp> Score: Balancing Simplicity, Practicality, and Predictive Value in Bleedingâ€Risk Assessment. Clinical Cardiology, 2015, 38, 562-564.	0.7	14
55	The <scp>HASâ€BLED</scp> Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Metaâ€analysis. Clinical Cardiology, 2015, 38, 555-561.	0.7	141

#	Article	IF	Citations
56	Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation. Chest, 2015, 148, 491-498.	0.4	9
58	Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. Chest, 2015, 148, 62-72.	0.4	40
59	Stroke prevention in atrial fibrillation: Where are we now?. Indian Heart Journal, 2015, 67, S1-S3.	0.2	1
60	Safety and efficacy of well managed warfarin. Thrombosis and Haemostasis, 2015, 113, 1370-1377.	1.8	127
61	Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thrombosis and Haemostasis, 2015, 114, 695-701.	1.8	45
62	A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial. Journal of Thrombosis and Haemostasis, 2015, 13, 1405-1413.	1.9	11
63	Comparison of the Abilities of Summary Measures of International Normalized Ratio Control to Predict Clinically Relevant Bleeding. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 524-531.	0.9	11
64	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. European Journal of Heart Failure, 2015, 17, 848-874.	2.9	32
65	Smoking, atrial fibrillation, and ischemic stroke. Current Opinion in Cardiology, 2015, 30, 512-517.	0.8	13
66	Non-valvular atrial fibrillation. Journal of Cardiovascular Medicine, 2015, 16, 491-496.	0.6	17
67	Association Between Usual Vitamin K Intake and Anticoagulation in Patients Under Warfarin Therapy. Clinical Nutrition Research, 2015, 4, 235.	0.5	9
68	Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients. Thrombosis and Haemostasis, 2015, 113, 881-890.	1.8	11
69	The SAMe-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anticoagulation?. Thrombosis and Haemostasis, 2015, 114, 657-659.	1.8	22
70	Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc â‰¥1, or higher?. Thrombosis and Haemostasis, 2015, 113, 1165-1169.	1.8	52
71	Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin. Thrombosis and Haemostasis, 2015, 114, 70-77.	1.8	13
72	Is risk-benefit of warfarin for atrial fibrillation with heart failure determined by heart failure severity?. Thrombosis and Haemostasis, 2015, 114, 1-3.	1.8	27
73	Non-vitamin K antagonist oral anticoagulants (NOACs) in the cardiac catherisation laboratory: Friends or Foes?. Thrombosis and Haemostasis, 2015, 114, 214-216.	1.8	1
74	Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Thrombosis and Haemostasis, 2015, 114, 1136-1143.	1.8	11

#	Article	IF	Citations
75	Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. Thrombosis and Haemostasis, 2015, 114, 826-834.	1.8	100
76	Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. Thrombosis and Haemostasis, 2015, 114, 768-777.	1.8	33
77	Editorsâ€™ Choice papers in Thrombosis and Haemostasis. Thrombosis and Haemostasis, 2015, 113, 217-220.	1.8	0
78	Comparison of Atrial Fibrillation Guidelines. Journal of General Internal Medicine, 2015, 30, 1404-1404.	1.3	0
79	The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. Thrombosis and Haemostasis, 2015, 113, 671-673.	1.8	19
80	Incidence of Myocardial Infarction and Vascular Death in Elderly Patients With Atrial Fibrillation Taking Anticoagulants. Chest, 2015, 147, 1644-1650.	0.4	59
81	â€˜Real worldâ€™ use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry. Thrombosis and Haemostasis, 2015, 113, 1159-1161.	1.8	18
82	Atrial fibrillation associated with increased risk of venous thromboembolism. Thrombosis and Haemostasis, 2015, 113, 185-192.	1.8	42
83	Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding. Circulation, 2015, 132, 517-525.	1.6	225
84	Stroke prevention in atrial fibrillation: changing concepts. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 76-79.	1.4	4
85	Non-steroidal anti-inflammatory drugs and incident atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 115-116.	1.4	1
86	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ³n CardÃaca y ElectrofisiologÃa (SOLEACE). Europace, 2015, 17, 1747-1769.	0.7	119
87	Nonsteroidal anti-inflammatory drugs and bleeding risk in anticoagulated patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2015, 13, 963-965.	0.6	9
88	Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. European Heart Journal, 2015, 36, 653-656.	1.0	58
89	Difficult decision making in the management of patients with atrial fibrillation and acute coronary syndrome or invasive cardiovascular interventions: new recommendations for daily practice. Europace, 2015, 17, 1319-1322.	0.7	5
90	Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation. Current Treatment Options in Neurology, 2015, 17, 331.	0.7	1
91	Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal. International Journal of Cardiology, 2015, 180, 246-254.	0.8	141
92	Fondaparinux in atrial fibrillation â€“ old dog, new tricks?. Archives of Cardiovascular Diseases, 2015, 108, 85-87.	0.7	1

#	Article	IF	Citations
93	Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation. Expert Opinion on Drug Safety, 2015, 14, 45-62.	1.0	6
95	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace, 2015, 17, 194-206.	0.7	41
96	Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?. Trends in Cardiovascular Medicine, 2015, 25, 315-336.	2.3	18
97	Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. Journal of Thrombosis and Haemostasis, 2015, 13, 495-504.	1.9	129
98	Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. Journal of Internal Medicine, 2015, 278, 1-18.	2.7	64
99	Comparative Efficacy and Safety of the Nonâ€“Vitamin K Antagonist Oral Anticoagulants for Patients with Nonvalvular Atrial Fibrillation. Seminars in Thrombosis and Hemostasis, 2015, 41, 146-153.	1.5	19
100	Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. American Journal of Medicine, 2015, 128, 1306-1313.e1.	0.6	135
101	Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic. Heart Rhythm, 2015, 12, 2332-2343.	0.3	36
102	Antidotes to non-vitamin K oral anticoagulants: necessary or not?. Expert Opinion on Pharmacotherapy, 2015, 16, 1573-1576.	0.9	7
103	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace, 2015, 17, 1169-1196.	0.7	138
104	Oral Anticoagulant Therapy in Atrial Fibrillation Patients at High Stroke and Bleeding Risk. Progress in Cardiovascular Diseases, 2015, 58, 177-194.	1.6	38
105	The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective â€˜Real-worldâ€™ Inception Cohort Study. American Journal of Medicine, 2015, 128, 1237-1243.	0.6	51
106	Switching from a vitamin K antagonist to a NOAC. Lancet Haematology,the, 2015, 2, e132-e133.	2.2	3
107	Intracranial Hemorrhage and Subsequent Ischemic Stroke in Patients With Atrial Fibrillation. Chest, 2015, 147, 1651-1658.	0.4	43
108	Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. Europace, 2015, 17, 507-508.	0.7	20
109	Optimizing Atrial Fibrillation Management. Chest, 2015, 148, 859-864.	0.4	43
110	A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. American Heart Journal, 2015, 169, 597-604.e5.	1.2	31
111	Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AFÂWith 0 or 1 Stroke Risk Factor Based on the CHA2DS2-VASc Score. Journal of the American College of Cardiology, 2015, 65, 1385-1394.	1.2	141

#	Article	IF	Citations
112	The SAMe-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. Europace, 2015, 17, 671-673.	0.7	16
113	Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 937-948.	1.5	4
114	Heart failure in patients with atrial fibrillation in Europe: a report from the <scp>EURObservational</scp> Research Programme Pilot survey on Atrial Fibrillation. European Journal of Heart Failure, 2015, 17, 570-582.	2.9	68
115	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clinical Research in Cardiology, 2015, 104, 418-429.	1.5	87
116	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2015, 13, 1155-1163.	0.6	1
117	Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace, 2015, 17, 1777-1786.	0.7	128
118	Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation. Stroke, 2015, 46, 3202-3207.	1.0	13
119	Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation. Journal of Comparative Effectiveness Research, 2015, 4, 367-376.	0.6	1
120	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace, 2015, 17, 1197-1214.	0.7	160
121	Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. Stroke, 2015, 46, 2830-2837.	1.0	6
122	Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT₂R₂score. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 150-152.	1.4	47
123	Sex differences in clinical characteristics and inpatient outcomes among 2442 hospitalized Chinese patients with nonvalvular atrial fibrillation: The Nanchang Atrial Fibrillation Project. International Journal of Cardiology, 2015, 201, 195-199.	0.8	7
124	Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors. European Heart Journal, 2015, 36, ehv415.	1.0	36
125	Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey. Archives of Cardiovascular Diseases, 2015, 108, 544-553.	0.7	17
126	Stroke Risk Perception in Atrial Fibrillation Patients is not Associated with Clinical Stroke Risk. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 2527-2532.	0.7	3
127	Matching the NOAC to the Patient. Journal of the American College of Cardiology, 2015, 66, 2282-2284.	1.2	31
128	Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. International Journal of Cardiology, 2015, 201, 513-516.	0.8	57
129	Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis. International Journal of Cardiology, 2015, 181, 247-254.	0.8	7

#	Article	IF	Citations
130	Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin. Stroke, 2015, 46, 23-30.	1.0	90
131	Stroke and Major Bleeding Risk in Elderly Patients Aged â‰¥75 Years With Atrial Fibrillation. Stroke, 2015, 46, 143-150.	1.0	116
132	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 386-386.	0.4	46
133	Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach. Expert Opinion on Drug Safety, 2015, 14, 7-20.	1.0	23
134	Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace, 2015, 17, 24-31.	0.7	164
135	Edoxaban in venous thromboembolism and stroke prevention: an appraisal. Vascular Health and Risk Management, 2016, 12, 45.	1.0	4
136	Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis â€“ Task Force on Anticoagulants in Heart Disease. Thrombosis and Haemostasis, 2016, 115, 685-711.	1.8	24
137	The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. Thrombosis and Haemostasis, 2016, 115, 1101-1108.	1.8	24
138	Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses. PLoS ONE, 2016, 11, e0157129.	1.1	11
139	How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?. European Heart Journal Supplements, 2016, 18, I1-I6.	0.0	1
140	Heparin monitoring: clinical outcome and practical approach. Annales De Biologie Clinique, 2016, 74, 637-652.	0.2	4
141	Stroke prevention in atrial fibrillation and â€˜real worldâ€™ adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. Scientific Reports, 2016, 6, 20432.	1.6	40
142	Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. Scientific Reports, 2016, 6, 24376.	1.6	49
143	Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view. Journal of Medical Economics, 2016, 19, 769-776.	1.0	13
144	Treatment of Atrial Fibrillation in Patients With Chronic Kidney Disease. Chest, 2016, 149, 891-892.	0.4	2
145	Degree of Anticoagulation Control in Patients With Atrial Fibrillation in Spain: Need to Minimize Biases and Contextualize Results. Response by Anguita SÃ¡nchez et al.. Revista Espanola De Cardiologia (English Ed), 2016, 69, 356.	0.4	0
146	Grado de control de la anticoagulaciÃ³n en pacientes con fibrilaciÃ³n auricular en EspaÃ±a: necesidad de minimizar sesgos y contextualizar resultados. Respuesta de Anguita SÃ¡nchez et al. Revista Espanola De Cardiologia, 2016, 69, 356.	0.6	1
147	Relation of the SAMe-TT 2 R 2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials. International Journal of Cardiology, 2016, 216, 168-172.	0.8	21

#	Article	IF	Citations
148	Net Clinical Benefit of Dabigatran Over Warfarin in Patients With Atrial Fibrillation Stratified by CHA2DS2-VASc and Time in Therapeutic Range. Canadian Journal of Cardiology, 2016, 32, 1247.e15-1247.e21.	0.8	16
149	Evolving Treatments for Arterial and Venous Thrombosis. Circulation Research, 2016, 118, 1409-1424.	2.0	96
150	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	0.6	754
151	Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. Expert Opinion on Pharmacotherapy, 2016, 17, 2033-2047.	0.9	4
152	A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation. Journal of Internal Medicine, 2016, 279, 467-476.	2.7	13
153	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	1.0	5,689
154	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	0.7	3,523
155	Design and Rationale of the <scp>REâ€ĐUAL PCI</scp> Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Clinical Cardiology, 2016, 39, 555-564.	0.7	65
156	Major bleeding risk among nonâ€valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a â€œrealâ€worldâ€•observational study in the United States. International Journal of Clinical Practice, 2016, 70, 752-763.	0.8	100
157	Stroke prevention in atrial fibrillation. Lancet, The, 2016, 388, 806-817.	6.3	329
158	Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion. Circulation Journal, 2016, 80, 605-612.	0.7	5
160	Patient knowledge of anticoagulant treatment does not correlate with treatment quality. Public Health, 2016, 141, 17-22.	1.4	5
161	Validation of a Modified CHA ₂ DS ₂ -VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation. Stroke, 2016, 47, 2462-2469.	1.0	78
162	Atrial Fibrillation and Thromboembolism inÂPatients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2016, 68, 1452-1464.	1.2	107
163	The Reality of â€œReal-Worldâ€•Data. Journal of the American College of Cardiology, 2016, 68, 1402-1403.	1.2	4
164	Effectiveness and safety of vitamin K-antagonists in an anticoagulant clinic. Thrombosis Research, 2016, 147, 122-123.	0.8	0
165	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Europace, 2017, 19, euw242.	0.7	67
166	Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thrombosis and Haemostasis, 2016, 116, 975-986.	1.8	224

#	Article	IF	Citations
167	Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. Clinical Research in Cardiology, 2016, 105, 912-920.	1.5	63
168	Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. EBioMedicine, 2016, 8, 309-316.	2.7	31
169	Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials). American Journal of Cardiology, 2016, 118, 72-78.	0.7	25
170	Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. Canadian Journal of Cardiology, 2016, 32, 1247.e23-1247.e28.	0.8	23
171	Individualized approaches to thromboprophylaxis in atrial fibrillation. American Heart Journal, 2016, 173, 143-158.	1.2	12
172	Emerging Tools for Stroke Prevention in Atrial Fibrillation. EBioMedicine, 2016, 4, 26-39.	2.7	15
173	The SAMe-TT2R2score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2016, 14, 177-187.	0.6	18
175	From clinical trials to real-world clinical practice: observations on the direct oral anticoagulants. Lancet Haematology,the, 2016, 3, e2-e3.	2.2	2
176	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. European Heart Journal, 2016, 38, ehv643.	1.0	69
177	Atrial Fibrillation and Stroke. Cardiology Clinics, 2016, 34, 317-328.	0.9	7
178	Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. Heart Failure Clinics, 2016, 12, 257-271.	1.0	8
179	Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage. Circulation, 2016, 133, 1540-1547.	1.6	103
181	Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clinical Research in Cardiology, 2016, 105, 412-420.	1.5	78
182	Different Heparin Contents in Prothrombin Complex Concentrates May Impair Blood Clotting in Outpatients With Ventricular Assist Devices Receiving Phenprocoumon. Journal of Cardiothoracic and Vascular Anesthesia, 2016, 30, 96-101.	0.6	10
183	Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation. Stroke, 2016, 47, 523-526.	1.0	34
184	Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50â€“69 years. European Heart Journal, 2016, 37, 2658-2667.	1.0	200
185	Preventing Thrombosis to Improve Outcomes in Heart Failure Patients. Progress in Cardiovascular Diseases, 2016, 58, 386-392.	1.6	6
186	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.	0.7	121

#	Article	IF	Citations
187	Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. American Journal of Medicine, 2016, 129, 600-607.	0.6	101
188	The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. Canadian Journal of Cardiology, 2016, 32, 336-343.	0.8	14
189	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. Europace, 2016, 18, 6-11.	0.7	38
190	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace, 2016, 18, 12-36.	0.7	66
191	Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 685-695.	0.7	1
194	Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. Clinical Research in Cardiology, 2017, 106, 420-427.	1.5	4
195	Intracardiac thrombi during warfarin anticoagulation - A case report and a brief literature review. Cor Et Vasa, 2017, 59, e277-e281.	0.1	4
196	Integrating genotypes in the SAMe-TT 2 R 2 score for the prediction of anticoagulation control in Chinese patients with atrial fibrillation on warfarin. International Journal of Cardiology, 2017, 241, 358-363.	0.8	7
197	Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry. American Heart Journal, 2017, 190, 86-93.	1.2	19
198	Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. Open Heart, 2017, 4, e000682.	0.9	27
199	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. New England Journal of Medicine, 2017, 377, 1513-1524.	13.9	1,099
200	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Scientific Reports, 2017, 7, 12066.	1.6	16
201	The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. American Heart Journal, 2017, 193, 16-22.	1.2	9
202	Management of atrial fibrillation and concomitant coronary artery disease. Continuing Cardiology Education, 2017, 3, 47-55.	0.4	8
203	The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey. Advances in Therapy, 2017, 34, 2043-2057.	1.3	17
204	Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. European Journal of Internal Medicine, 2017, 46, 6-10.	1.0	16
205	Personalized Anticoagulation. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	8
206	The role of oral anticoagulant therapy in patients with acute coronary syndrome. Therapeutic Advances in Hematology, 2017, 8, 353-366.	1.1	21

#	Article	IF	Citations
207	Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. Expert Opinion on Drug Safety, 2017, 16, 1051-1062.	1.0	24
208	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). European Journal of Preventive Cardiology, 2017, 24, 4-40.	0.8	83
209	Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thrombosis and Haemostasis, 2017, 117, 1448-1454.	1.8	74
210	Stroke prevention in atrial fibrillation: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1230-1239.	1.8	346
211	Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Thrombosis and Haemostasis, 2017, 117, 209-218.	1.8	161
212	Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 700-712.	0.5	12
213	Stroke prevention in atrial fibrillation. Journal of the Royal College of Physicians of Edinburgh, The, 2017, 47, 13-23.	0.2	3
214	Treatment of cancer-associated venous thromboembolism by new oral anticoagulants: a meta-analysis. Journal of Xiangya Medicine, 0, 2, 55-55.	0.2	1
215	Control of IBMIR Induced by Fresh and Cryopreserved Hepatocytes by Low Molecular Weight Dextran Sulfate versus Heparin. Cell Transplantation, 2017, 26, 71-81.	1.2	11
216	TRATAMIENTO ANTICOAGULANTE ORAL CON Ã‰NFASIS EN SUS INDICACIONES EN CARDIOLOGÃA. Revista MÃ©dica ClÃnica Las Condes, 2018, 29, 76-86.	0.2	0
217	State of play and future direction with NOACs: An expert consensus. Vascular Pharmacology, 2018, 106, 9-21.	1.0	9
218	Comparing Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) to Different Coumadins: The Win-Win Scenarios. Thrombosis and Haemostasis, 2018, 118, 803-805.	1.8	7
219	Optimizing Vitamin K Antagonist Treatment in Patients with Mechanical Heart Valve Prosthesis. Thrombosis and Haemostasis, 2018, 118, 806-807.	1.8	1
220	Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. International Journal of Clinical Practice, 2018, 72, e13069.	0.8	4
221	Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (FACILITA study). Current Medical Research and Opinion, 2018, 34, 1301-1308.	0.9	21
222	Quality of oral anticoagulation with vitamin K antagonists in â€˜real-worldâ€™ patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. Europace, 2018, 20, 1435-1441.	0.7	39
223	Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. Clinical Therapeutics, 2018, 40, 114-122.	1.1	21
225	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the â€œReal-Worldâ€•vs Clinical Trials. Mayo Clinic Proceedings, 2018, 93, 1065-1073.	1.4	28

#	Article	IF	Citations
226	Optimal nonvitamin K antagonist oral anticoagulant therapy in a warfarin-sensitive patient after left atrial appendage closure. Medicine (United States), 2018, 97, e0683.	0.4	3
228	Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nature Reviews Nephrology, 2018, 14, 337-351.	4.1	89
230	The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 328-336.	0.3	3
231	First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 914-919.	0.7	11
232	The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. Expert Review of Hematology, 2018, 11, 5-12.	1.0	17
233	Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: A review. Heart Rhythm, 2018, 15, 615-623.	0.3	23
234	Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in â€˜real-worldâ€™ atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. International Journal of Cardiology, 2018, 254, 125-131.	0.8	18
235	Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort. Journal of Thrombosis and Haemostasis, 2018, 16, 116-124.	1.9	6
236	Surgical embolectomy for acute massive pulmonary embolism: state of the art. Journal of Thoracic Disease, 2018, 10, 5154-5161.	0.6	26
237	Tromboembolismo pulmonar. Medicine, 2018, 12, 3971-3981.	0.0	0
239	Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke, 2018, 49, 2933-2944.	1.0	246
240	Nonâ€“Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves. Circulation, 2018, 138, 1356-1365.	1.6	30
241	Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. PLoS ONE, 2018, 13, e0205989.	1.1	47
242	Current and emerging pharmacotherapy for ischemic stroke prevention in patients with atrial fibrillation. Expert Opinion on Pharmacotherapy, 2018, 19, 1999-2009.	0.9	2
243	Real-World Safety of Anticoagulants. , 2018, , .		0
244	Oral anticoagulation and comorbidities; too many details for clinical practice?. International Journal of Cardiology, 2018, 264, 93-94.	0.8	1
245	Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population. BMJ Open, 2018, 8, e020676.	0.8	14
246	Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble. Drugs, 2018, 78, 1309-1319.	4.9	1

#	Article	IF	Citations
247	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2018, 154, 1121-1201.	0.4	718
248	Clinical usefulness of the SAMe-TT2R2 score: A systematic review and simulation meta-analysis. PLoS ONE, 2018, 13, e0194208.	1.1	12
249	Poor warfarin anticoagulation in long-term thromboprophylaxis: a survey in a southern Croatian county. Croatian Medical Journal, 2019, 60, 2-11.	0.2	3
250	Therapeutic effect of vitamin K1 combined with meropenem on the treatment of pertussis syndrome. Experimental and Therapeutic Medicine, 2019, 18, 642-646.	0.8	2
251	Real-world persistence with direct oral anticoagulants (DOACs) in naÃ¯ve patients with non-valvular atrial fibrillation. International Journal of Cardiology, 2019, 288, 72-75.	0.8	17
252	Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation. Scientific Reports, 2019, 9, 6690.	1.6	15
253	Antiplatelet Drugs in the Management of Coronary Artery Disease. , 2019, , 1017-1029.		0
254	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal, 2019, 213, 35-46.	1.2	45
255	Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 381-398.	1.5	34
256	Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE. Thrombosis and Haemostasis, 2019, 119, 675-684.	1.8	9
257	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. BMJ Open, 2019, 9, e033712.	0.8	3
258	Prognostic value of the model for end-stage liver disease excluding INR score (MELD-XI) in patients with adult congenital heart disease. PLoS ONE, 2019, 14, e0225403.	1.1	13
259	Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney Transplantation. Frontiers in Immunology, 2019, 10, 2912.	2.2	16
260	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section Vâ€"Special Situations. Thrombosis and Haemostasis, 2019, 119, 014-038.	1.8	28
261	Predictors for INR-control in a well-managed warfarin treatment setting. Journal of Thrombosis and Thrombolysis, 2019, 47, 227-232.	1.0	10
262	The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. International Journal of Clinical Practice, 2019, 73, e13285.	0.8	11
263	Oral Anticoagulation in the Elderly: New Oral Anticoagulantsâ€"Innovative Solution for an Old Problem?. American Journal of Therapeutics, 2019, 26, e133-e142.	0.5	5
264	Evaluation of the Validity of SAMe-TT₂R₂ Score in a Cohort of Venous Thromboembolism Patients Treated With Warfarin. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962094503.	0.7	1

#	Article	IF	Citations
265	Quality of oral anticoagulation control in Chinese patients with non-valvular atrial fibrillation: a prospective controlled study. Current Medical Research and Opinion, 2020, 36, 1433-1439.	0.9	5
266	Is the time in therapeutic range on coumarins predicted by previous time in therapeutic range?. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 604-609.	1.0	3
267	Hemorrhage Risk Profiles among Different Antithrombotic Regimens: Evidence from a Real-World Analysis of Postmarketing Surveillance Data. Cardiovascular Drugs and Therapy, 2022, 36, 103-112.	1.3	6
268	A nurseâ€led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes. International Journal of Clinical Practice, 2020, 74, e13634.	0.8	13
269	Mediterranean Diet Decreases the Initiation of Use of Vitamin K Epoxide Reductase Inhibitors and Their Associated Cardiovascular Risk: A Randomized Controlled Trial. Nutrients, 2020, 12, 3895.	1.7	5
270	Effectiveness and Safety of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus. Mayo Clinic Proceedings, 2020, 95, 929-943.	1.4	20
271	Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation. Thrombosis Research, 2020, 192, 12-20.	0.8	12
272	Evaluation of the clinical and safety outcomes of face-to-face vs a telephonic model of a pharmacist-led outpatient anticoagulation service. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 1444.	0.5	3
273	Specialized Management of Oral Anticoagulation Therapy Improves Outcome in Patients with Chronic Renal Insufficiency. Journal of Clinical Medicine, 2020, 9, 645.	1.0	2
274	Characteristics and anticoagulant treatment status of elderly non-valvular atrial fibrillation patients with a history of catheter ablation in Japan: Subanalysis of the ANAFIE registry. Journal of Cardiology, 2020, 76, 446-452.	0.8	4
275	Vitamin K antagonists and osteoporotic fractures: insights from comparisons with the NOACs. European Heart Journal, 2020, 41, 1109-1111.	1.0	7
276	Standardization of Prothrombin Time/International Normalized Ratio (PT/INR). International Journal of Laboratory Hematology, 2021, 43, 21-28.	0.7	43
277	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	1.0	5,583
278	Electronic monitoring of adherence to onceâ€daily and twiceâ€daily direct oral anticoagulants in patients with atrial fibrillation: Baseline data from the SMAAPâ€AF trial. Journal of Arrhythmia, 2021, 37, 616-625.	0.5	3
279	Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: Perspectives on improving patient care. Expert Review of Cardiovascular Therapy, 2021, 19, 221-236.	0.6	2
280	Efficacy and Safety of the Fixed-Dose Versus Variable-Dose of 4-PCC for Vitamin K Antagonist Reversal: A Comprehensive Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy, 2022, 36, 533-546.	1.3	8
281	Use of Non-VitaminÂK Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity. Advances in Therapy, 2021, 38, 3166-3184.	1.3	6
282	Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions. Rational Pharmacotherapy in Cardiology, 2021, 17, 206-211.	0.3	1

#	Article	IF	Citations
284	Cnidoscolus Aconitifolius (Mill.) I.M. Johnst.: A Food Proposal Against Thromboembolic Diseases. Food Reviews International, 2023, 39, 1377-1410.	4.3	1
285	Heart failure and atrial fibrillation: new concepts in pathophysiology, management, and future directions. Heart Failure Reviews, 2022, 27, 1201-1210.	1.7	18
286	2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology, 2021, 26, 4594.	0.4	89
287	Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta-analysis of real-world evidences. Egyptian Heart Journal, 2021, 73, 70.	0.4	16
288	2021 Korean Heart Rhythm Society Guidelines for Stroke Prevention in Atrial Fibrillation. Korean Journal of Medicine, 2021, 96, 296-311.	0.1	1
289	Management of patients receiving novel antithrombotic treatment in endodontic practice: Review and clinical recommendations. International Endodontic Journal, 2021, 54, 1754-1768.	2.3	1
290	Eighty years of oral anticoagulation: Learning from history. Vascular Pharmacology, 2021, 141, 106918.	1.0	2
291	Is It Safe (and When) to Stop Oral Anticoagulation After Ablation for Atrial fibrillation? (Do We Have) Tj ETQq1 1 0.784314 rgBT /Over	1.3	1
292	Antithrombotika und AntihÃmorrhagika. , 2016, , 351-368.		2
293	Antithrombotika und AntihÃmorrhagika. , 2017, , 353-372.		1
294	Antithrombotika und AntihÃmorrhagika. , 2018, , 401-421.		3
295	Antithrombotika und AntihÃmorrhagika. , 2019, , 531-555.		8
296	Publisherâ€™s note. European Heart Journal, 2015, 36, 2880-5.	1.0	25
297	Use of the SAMe-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke Incidence. PLoS ONE, 2016, 11, e0150674.	1.1	41
298	The Potential Role of Edoxaban in Stroke Prevention Guidelines. Arrhythmia and Electrophysiology Review, 2014, 3, 40-43.	1.3	2
299	Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis. Oncotarget, 2017, 8, 109703-109711.	0.8	24
300	2018 KHRS Expert Consensus Recommendation for Oral Anticoagulants Choice and Appropriate Doses: Specific Situation and High Risk Patients. Korean Journal of Medicine, 2018, 93, 110-132.	0.1	6
301	2018 KHRS Guidelines for Stroke Prevention Therapy in Korean Patients with Nonvalvular Atrial Fibrillation. Korean Journal of Medicine, 2018, 93, 87-109.	0.1	8

#	Article	IF	Citations
302	Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. EuroIntervention, 2015, 10, 1015-1021.	1.4	21
303	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. EuroIntervention, 2015, 10, 1095-1108.	1.4	29
304	Stability of vitamin K antagonist anticoagulation after COVIDâ€19 diagnosis. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12597.	1.0	3
305	Efficacy and Safety of Direct Oral Anticoagulants in Patients with Diabetes and Nonvalvular Atrial Fibrillation: Meta-Analysis of Observational Studies. Cardiovascular Therapeutics, 2021, 2021, 1-14.	1.1	4
306	The concept of dose modification for lowering the risk of bleeding with non-vitamin k oral anticoagulant drugs: How to choose the right dose?. Srce I Krvni Sudovi, 2014, 33, 216-219.	0.1	0
307	Pulmoner Embolinin GÃ¼ncel Tedavisi. Arsiv Kaynak Tarama Dergisi, 0, , 433-455.	0.1	0
308	Empirical anticoagulation for patients in sinus rhythm at high risk of ischaemic stroke: A review of current literature. World Journal of Cardiology, 2017, 9, 422.	0.5	1
309	Anticoagulants for Atrial Fibrillation. Cardiovascular Medicine, 2017, , 105-114.	0.0	0
311	Syncope; the Initial Manifestation of Pulmonary Embolism: A Case Report. SSRN Electronic Journal, 0, , .	0.4	0
312	Syncope; the Initial Manifestation of Pulmonary Embolism: A Case Report. Journal of Advances in Medical and Biomedical Research, 2018, 26, 48-51.	0.1	0
313	Beneficios y riesgos de los anticoagulantes orales en la fibrilaciÃ³n auricular. Revista Espanola De Cardiologia Suplementos, 2019, 18, 9-14.	0.2	0
314	Conclusiones y recomendaciones prÃ¡cticas. Revista Espanola De Cardiologia Suplementos, 2019, 18, 34-40.	0.2	0
315	Antithrombotika und AntihÃmorrhagika. , 2020, , 395-420.		0
316	Incidence Rates of Bleeding and Emergency Surgery Due to Trauma or Fracture Among Japanese Patients with Non-valvular Atrial Fibrillation Receiving Oral Anticoagulation Therapy. Cardiology and Therapy, 2020, 9, 189-199.	1.1	4
317	Central directions for reducing cardiovascular mortality: what can be changed today?. Russian Journal of Cardiology, 2020, 25, 3983.	0.4	12
318	Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy. Cardiovascular & Hematological Disorders Drug Targets, 2021, 21, 123-127.	0.2	1
319	Can venous thromboembolism navigate the prevention of cardiovascular complications?. Annals of Translational Medicine, 2015, 3, 116.	0.7	0
320	Management of Atrial Fibrillation in Patients With Kidney Disease. Journal of Atrial Fibrillation, 2014, 6, 989.	0.5	1

#	Article	IF	Citations
321	Comparing Safety and Efficacy of Dabigatran and Factor Xa Inhibitors for Stroke Prevention in Hemophiliacs with Non-Valvular Atrial Fibrillation. Journal of Atrial Fibrillation, 2019, 12, 2157.	0.5	0
322	Anticoagulation for atrial fibrillation in heart failure patients: balancing between Scylla and Charybdis. Journal of Geriatric Cardiology, 2021, 18, 352-361.	0.2	1
323	Antithrombotika und AntihÃmorrhagika. , 2021, , 299-326.		3
324	The Effect of Serum Magnesium Level on Stable Anticoagulation in Patients Using Warfarin for Various Cardiac Indications. Biological Trace Element Research, 2022, 200, 4297-4302.	1.9	1
325	Vitamin K-dependent anticoagulant use and level of anticoagulation control in sub-Saharan Africa: protocol for a retrospective cohort study. BMJ Open, 2022, 12, e057166.	0.8	1
326	Efficacy and Safety Profile of Novel Oral Anticoagulants in the Treatment of Left Atrial Thrombosis: A Systematic Review and Meta-Analysis. Current Therapeutic Research, 2022, 96, 100670.	0.5	1
328	Time trends in adherence to guideline recommendations for anticoagulation therapy in patients with atrial fibrillation and myocardial infarction. Open Heart, 2022, 9, e001934.	0.9	2
333	Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study. PLoS Medicine, 2022, 19, e1004003.	3.9	10
335	Antithrombotic treatment switching in elderly patients with atrial fibrillation and the risk of thromboembolism, bleeding, and cardiac death. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	1.0	0
336	Efficacy and Safety of NOACs Compared With VKAs for Patients With Atrial Fibrillation After Transcatheter Aortic Valve Implantation: A System Review and Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211451.	0.7	0
337	Pattern of oral anticoagulant prescribing for atrial fibrillation in general practice: an observational study in The Netherlands. BJGP Open, 2023, 7, BJGPO.2022.0179.	0.9	1
338	Antithrombotische Therapie. , 2022, , 233-263.		0
339	Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study. PLoS ONE, 2023, 18, e0284425.	1.1	0
342	Synthetic coumarin derivatives with anticoagulation and antiplatelet aggregation inhibitory effects. Medicinal Chemistry Research, 2023, 32, 2269-2278.	1.1	1
344	Vitamin-K-Antagonisten. Springer Reference Medizin, 2023, , 1-12.	0.0	0
346	Antithrombotische Therapie. , 2023, , 255-287.		0